Aware Super Pty Ltd as trustee of Aware Super Purchases New Shares in Bristol Myers Squibb Company $BMY

Aware Super Pty Ltd as trustee of Aware Super purchased a new position in Bristol Myers Squibb Company (NYSE:BMY) in the 1st quarter, HoldingsChannel.com reports. The fund purchased 328,003 shares of the biopharmaceutical company’s stock, valued at approximately $19,893,000.

A number of other large investors also recently added to or reduced their stakes in the stock. W.G. Shaheen & Associates DBA Whitney & Co increased its position in shares of Bristol Myers Squibb by 5.0% during the first quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 13,802 shares of the biopharmaceutical company’s stock worth $837,000 after purchasing an additional 663 shares in the last quarter. Delta Financial Advisors LLC lifted its holdings in Bristol Myers Squibb by 1.6% in the 1st quarter. Delta Financial Advisors LLC now owns 26,446 shares of the biopharmaceutical company’s stock valued at $1,604,000 after purchasing an additional 420 shares in the last quarter. Wealthfront Advisers LLC lifted its holdings in Bristol Myers Squibb by 20.5% in the 1st quarter. Wealthfront Advisers LLC now owns 427,748 shares of the biopharmaceutical company’s stock valued at $25,943,000 after purchasing an additional 72,630 shares in the last quarter. D.A. Davidson & CO. boosted its stake in Bristol Myers Squibb by 2.6% during the 1st quarter. D.A. Davidson & CO. now owns 302,594 shares of the biopharmaceutical company’s stock worth $18,352,000 after purchasing an additional 7,665 shares during the last quarter. Finally, Twin Capital Management Inc. grew its holdings in shares of Bristol Myers Squibb by 0.3% during the first quarter. Twin Capital Management Inc. now owns 78,220 shares of the biopharmaceutical company’s stock worth $4,744,000 after buying an additional 218 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA accepted Bristol Myers Squibb’s NDA for mezigdomide in combination therapy for relapsed or refractory multiple myeloma, a meaningful regulatory step that supports the company’s oncology pipeline and future revenue potential. Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma
• Positive Sentiment: Unusually heavy call option buying suggested traders were positioning for further upside in BMY, with call volume well above normal levels.
• Positive Sentiment: Recent coverage highlighted Bristol Myers Squibb as a strong value stock and noted that its earnings surprise history could support another potential beat in the next quarterly report. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: BMY continued to attract investor attention and broad market discussion, which can amplify trading interest even without a specific new catalyst. Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Wells Fargo reportedly assigned a Hold rating, and one market note said the stock underperformed peers earlier in the week, which may have tempered some enthusiasm. Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $60.47 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The company has a 50-day moving average price of $56.93 and a 200 day moving average price of $57.76. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The stock has a market cap of $123.48 billion, a P/E ratio of 16.99, a PEG ratio of 0.17 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period in the previous year, the business posted $1.80 EPS. Bristol Myers Squibb’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.34 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on BMY shares. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Guggenheim reaffirmed a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $54.00 price objective on shares of Bristol Myers Squibb in a report on Monday, July 6th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 2nd. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Bristol Myers Squibb has an average rating of “Hold” and a consensus price target of $61.25.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.